Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from BTIG Research

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a report released on Tuesday,Benzinga reports.

IVVD has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Invivyd in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

Invivyd Trading Down 6.7%

IVVD opened at $0.83 on Tuesday. The firm’s fifty day moving average is $1.12 and its two-hundred day moving average is $1.62. Invivyd has a twelve month low of $0.48 and a twelve month high of $3.07.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The firm had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. As a group, equities analysts expect that Invivyd will post -0.5 earnings per share for the current year.

Institutional Investors Weigh In On Invivyd

Several large investors have recently made changes to their positions in the stock. Courier Capital LLC acquired a new stake in shares of Invivyd during the fourth quarter worth $25,000. Chicago Partners Investment Group LLC acquired a new position in Invivyd in the 1st quarter worth $25,000. Bronte Capital Management Pty Ltd. acquired a new position in Invivyd in the 4th quarter worth $27,000. DRW Securities LLC acquired a new position in Invivyd in the 4th quarter worth $27,000. Finally, ProShare Advisors LLC bought a new position in Invivyd during the 4th quarter worth about $30,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.